0000950170-24-029040.txt : 20240311 0000950170-24-029040.hdr.sgml : 20240311 20240311125459 ACCESSION NUMBER: 0000950170-24-029040 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240307 FILED AS OF DATE: 20240311 DATE AS OF CHANGE: 20240311 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Fust Matthew K CENTRAL INDEX KEY: 0001397266 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36276 FILM NUMBER: 24737287 MAIL ADDRESS: STREET 1: C/O ULTRAGENYX PHARMACEUTICAL INC. STREET 2: 60 LEVERONI COURT CITY: NOVATO STATE: CA ZIP: 94949 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Ultragenyx Pharmaceutical Inc. CENTRAL INDEX KEY: 0001515673 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 272546083 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 60 LEVERONI COURT CITY: NOVATO STATE: CA ZIP: 94949 BUSINESS PHONE: 415-483-8800 MAIL ADDRESS: STREET 1: 60 LEVERONI COURT CITY: NOVATO STATE: CA ZIP: 94949 4 1 ownership.xml 4 X0508 4 2024-03-07 0001515673 Ultragenyx Pharmaceutical Inc. RARE 0001397266 Fust Matthew K C/O ULTRAGENYX PHARMACEUTICAL INC. 60 LEVERONI COURT NOVATO CA 94949 true false false false true Common Stock 2024-03-07 4 S false 2550 50.89 D 24505 D Common Stock 2024-03-07 4 S false 2145 50.85 D 22360 D Common Stock 2024-03-07 4 S false 7500 50.88 D 14860 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.53 to $51.78 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $51.78 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. /s/ Karah Parschauer, attorney-in-fact 2024-03-11